



TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

MARK B. WILSON
PARTNER

INTERNET ADDRESS:
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035

April 23, 2002

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP


600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG
FILE: WIRO:016US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 23, 2002	
Date	Mark B. Wilson

Commissioner for Patents
Washington, DC 20231

RE: *SN 10/047,990 "METHODS OF INDUCING CELL DEATH" – Kevin Leon Gaston et al. (Client Reference: P100147US-PCT/JPD/SMH)*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1, B1-B7, C1-C11).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200665/MBW.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259

MBW/cmb

Encl: as noted



UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

In re Application of:
Kevin Leon Gaston *et al.*

Serial No.: 10/047,990


Filed: January 14, 2002

For: METHODS OF INDUCING CELL
DEATH

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: WIRO:016US/MBW

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 23, 2002	
Date	Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10200665/MBW.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 23, 2002

Form PT-1449 (modified)

Atty. Docket No.
WIRO:016US/MBWSerial No.
10/047,990

RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
January 14, 2002Group:
1645U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,601,973	2/11/97	Müller <i>et al.</i>	435	5	5/3/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0523395	1/20/93	Europe			
	B2	WO 92/05248	4/2/92	PCT			
	B3	WO 92/12728	8/6/92	PCT			
	B4	WO 94/04686	3/3/94	PCT			
	B5	WO 95/04151	2/9/95	PCT			
	B6	WO 98/01148	1/15/98	PCT			
	B7	WO 98/32861	7/30/98	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Davidson <i>et al.</i> , "Human T cell responses to HPV 16 E2 generated with monocyte-derived dendritic cells," <i>Int. J. Cancer</i> , 94:807-812, 2001.
	C2	Desaintes <i>et al.</i> , "Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis," <i>The EMBO Journal</i> , 15:504-514, 1997.
	C3	Frattoni <i>et al.</i> , "Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein," <i>The EMBO Journal</i> , 16:318-331, 1997.
	C4	Goodwin <i>et al.</i> , "Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines," <i>J. Virology</i> , 72:3925-3934, 1998.

25158236.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
WIRO:016US/MBWSerial No.
10/047,990

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Kevin Leon Gaston *et al.*Filing Date:
January 14, 2002Group:
1645U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Hickman <i>et al.</i> , "Perturbation of the p53 response by human papillomavirus type 16 E7," <i>J. Virology</i> , 71:3710-3718, 1997.
	C6	Jones <i>et al.</i> , "Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis," <i>Virology</i> , 239:97-107, 1997.
	C7	Nakamura <i>et al.</i> , "A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis," <i>Oncogene</i> , 14:2991-2998, 1997.
	C8	Sanchez-Perez <i>et al.</i> , "Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis," <i>J. General Virology</i> , 78:3009-3018, 1997.
	C9	Stöppler <i>et al.</i> , "The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes," <i>Oncogene</i> , 17:1207-1214, 1998.
	C10	Webster <i>et al.</i> , "The human papillomavir (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway," <i>J. Biol. Chem.</i> , 275:87-94, 2000.
	C11	Webster <i>et al.</i> , "The induction of apoptotic cell death by the HPV 16 E2 protein," <i>Biochemical Society Transactions</i> , 27:A97, 1999.

25158236.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



RECEIVED

MAY 02 2002

TECH CENTER 1600/2900